These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27029060)

  • 1. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
    Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
    Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
    Chen CH; Changou CA; Hsieh TH; Lee YC; Chu CY; Hsu KC; Wang HC; Lin YC; Lo YN; Liu YR; Liou JP; Yen Y
    Clin Cancer Res; 2018 Mar; 24(5):1176-1189. PubMed ID: 29222162
    [No Abstract]   [Full Text] [Related]  

  • 3. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
    Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
    PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
    Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
    Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
    Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
    Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.
    Jiang K; Tang X; Guo J; He R; Chan S; Song X; Tu Z; Wang Y; Ren X; Ding K; Zhang Z
    Cancer Med; 2021 Jul; 10(14):4874-4884. PubMed ID: 34114373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
    Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
    He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
    Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
    Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
    Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
    Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
    Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
    Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
    Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
    Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.